Navigation Links
Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
Date:12/4/2007

NEW YORK, Dec. 4 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that Alan J. Lacy has been elected to its Board of Directors, effective January 2, 2008. Lacy will serve as a member of the Audit Committee.

Lacy, 54, is currently a senior advisor to Oak Hill Capital Partners, L.P., a private equity investment firm. From 1994 to 2006, he was employed by Sears, Roebuck and Co. and following the acquisition of the company, Sears Holdings Corporation. He held executive level positions of increasing responsibility in finance and operations, including his service as chief executive officer from 2000 to 2005. He also served as vice chairman from 2005 to 2006.

"We are very pleased to have a person of Alan's broad business and financial experience join our Board," said James D. Robinson III, chairman, Bristol-Myers Squibb. "His addition adds to an already outstanding group of directors."

"Alan is a man of high integrity and business acumen," added James M. Cornelius, chief executive officer, Bristol-Myers Squibb. "We look forward to his contributions as a director of our company as we continue to evolve into a next generation biopharma enterprise."

Bristol-Myers Squibb is a global biopharmaceutical and related healthcare products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Bristol-Myers Squibb Announces Dividend
2. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
3. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
4. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
5. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
6. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
7. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
8. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
9. Mediware Names Thomas K. Mann Chief Executive Officer
10. Cleveland-based Health Care Tech Company Within3 Names New CEO
11. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... a year and a half of planning the Multiple Pathways of Recovery Conference , ... Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel & ... explore the many pathways individuals use to get into and sustain their recovery. Pathways ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross ... and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their ... Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ ...
(Date:5/27/2016)... ... 27, 2016 , ... An influential resource amongst nurses and professionals in the ... on the variety of topics detailing why we appreciate nurses in so many different ... has gone from being in a major recession to one of the hottest growing ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... factors of a stroke, which we as a society can control and change. , ... stroke occurs nearly every 40 seconds within the United States. Plus, with an estimated ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 ... H1 2016"market research report that provides an overview ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/24/2016)... AMSTERDAM , May 24, 2016 ... aplicación médica para ayudar a los médicos a compartir ... los pacientes a escala mundial. Profesionales médicos de Europa, ... ya se han apuntado a la aplicación, que combina ... en un entorno totalmente seguro. Educación   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology: